Oral administration of 24,25(OH)2D3 suppresses the serum parathyroid hormone levels of dialysis patients

D. Ben-Ezer, S. Shany, A. Conforty, J. Rapoport, S. Edelstein, T. Bdolah-Abram, D. R. Kafka, C. Chaimovitz

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

We measured the serum parathyroid hormone (PTH) levels in 20 patients treated with continuous ambulatory peritoneal dialysis before and after oral treatment with 24,25-dihydroxyvitamin D3- 24,25(OH)2D3. This metabolite was given in addition to existing treatment with 1α-OH-D3 and calcium carbonate. Administration of 24,25(OH)2D3 led to a significant decrease in PTH levels (intact molecule) from 382 ± (SE) 65 to 245 ± 54 pg/ml in 9 patients whose initial levels were extremely high (p = 0.01). No side effects were observed. On the average, calcium values were unchanged and within the normal range throughout the study period; however, a few episodes of mild asymptomatic hypercalcemia occurred which responded quickly to reduction of the calcium carbonate dosage. The present study suggests that oral administration of 24,25(OH)2D3 combined with Iα-OH-D3 is safe and capable of suppressing the raised serum PTH levels of end-stage renal disease patients without the danger of significant hypercalcemia.

Original languageEnglish
Pages (from-to)283-287
Number of pages5
JournalNephron
Volume58
Issue number3
StatePublished - 1 Jan 1991
Externally publishedYes

Keywords

  • 1,25(OH)D
  • 24,25(OH)D
  • continuous ambulatory peritoneal dialysis
  • end-stage renal disease
  • secondary hyperparathyroidism

Fingerprint

Dive into the research topics of 'Oral administration of 24,25(OH)<sub>2</sub>D<sub>3</sub> suppresses the serum parathyroid hormone levels of dialysis patients'. Together they form a unique fingerprint.

Cite this